BAX - Baxter International Inc. Последние новости | Finranks

16.06.2026

Reasons to Retain Baxter International Stock in Your Portfolio for Now

BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.

09.06.2026

Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

13.05.2026

Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10.05.2026

Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting

Baxter International NYSE: BAX held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the election of nine directors, executive compensation, auditor ratification, an amended incentive plan and a change related to board size.

08.05.2026

Baxter International Still Has A Path To Upside

In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.

05.05.2026

Madison Small Cap Fund Q1 2026 Portfolio Activity

ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.

30.04.2026

BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract

Baxter beats Q1 earnings and revenue estimates, sending shares higher despite declining profits and margin contraction.

Видео

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
BAX	Argus	Hold	undefined >> undefined	October 31st 2025
BAX	Stifel	Hold	undefined >> $25	August 4th 2025
BAX	Goldman	Neutral	undefined >> $25	August 1st 2025
BAX	Goldman	Buy	undefined >> $42	February 26th 2025
BAX	Argus	Buy	undefined >> undefined	February 24th 2025
BAX	Barclays	Overweight	undefined >> $39	February 20th 2025

Пресс-релизы

30.04.2026

Baxter Reports First-Quarter 2026 Results

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter continues to take the decisive steps nec.

Baxter International Inc. (BAX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты